Open AccessS206: OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG‐TERM BENEFIT OVER RITUXIMAB PLUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: FINAL ANALYSIS OF THE GALLIUM STUDY
Author(s) -
Townsend W.,
Hiddemann W.,
Buske C.,
Cartron G.,
Cunningham D.,
Dyer M. J.,
Gribben J.,
Phillips E.,
Dreyling M.,
Seymour J. F.,
Grigg A.,
Lin T.Y.,
Hong X.N.,
Kingbiel D.,
Nielsen T. G.,
Knapp A.,
Herold M.,
Marcus R.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843716.68800.8b
Subject(s) - obinutuzumab , medicine , bendamustine , rituximab , vincristine , follicular lymphoma , chop , chemotherapy , oncology , gastroenterology , febrile neutropenia , cyclophosphamide , clinical endpoint , neutropenia , surgery , lymphoma , randomized controlled trial